TrialInternational journal of hematology2024

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.

Koji Kato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.